As­traZeneca cuts PhI­II tri­al short af­ter next-gen check­point drug fails in­ter­im analy­sis

Four years af­ter promis­ing ear­ly da­ta in head and neck can­cer drew As­traZeneca to a big-mon­ey deal with In­nate Phar­ma around its next-gen­er­a­tion check­point in­hibitor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER